Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas
暂无分享,去创建一个
E. Kimby | J. Delabie | H. Holte | M. Erlanson | H. Hagberg | Björn Östenstad | O. Lindén | C. Sundström | P. Brown | B. Wahlin | A. Johansson | T. Ahlgren | K. Wader
[1] R. Gascoyne,et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] W. Hiddemann,et al. How we manage follicular lymphoma , 2014, Leukemia.
[3] R. Stephens,et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. , 2014, The Lancet. Oncology.
[4] L. Gordon,et al. Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database , 2013, British journal of haematology.
[5] J. Cerhan,et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Summer S. Han,et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.
[7] R. Houot,et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma , 2013, Haematologica.
[8] S. Montoto,et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Andrew Lister,et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.
[10] M. Ghielmini,et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Rossi,et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.
[12] R. Marcus,et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] E. Kimby,et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group , 2008, Leukemia & lymphoma.
[14] T. Ittel,et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Schwarzer,et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.
[16] G. Ayers,et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[18] R. Fisher,et al. New treatment options have changed the survival of patients with follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Hagenbeek,et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[21] L. Trümper. From bench to bedside , 2005, Medizinische Klinik.
[22] Hervé Watier,et al. From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.
[23] P. Colombat,et al. Rituximab-Dependent Cytotoxicity by Natural Killer Cells , 2004, Cancer Research.
[24] M. Ghielmini,et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.
[25] K. Maclennan,et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.
[26] D. Hossfeld. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .
[27] S. Sacchi,et al. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. , 2001, Haematologica.
[28] G. Salles,et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. , 2001, Blood.
[29] D. Maloney,et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] J. Hainsworth,et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. , 2000, Blood.
[31] K. Fornataro,et al. New Treatment Options , 1999, The Body positive.
[32] R. Doherty. Long term follow up , 1999, BMJ.
[33] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] T. Lister,et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Scheinberg,et al. Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.
[36] R. Warnke,et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. , 1989, Blood.
[37] I. Bernstein,et al. Comparison of combinations of interferons with tumor specific and nonspecific monoclonal antibodies as therapy for murine B- and T-cell lymphomas. , 1988, Cancer research.
[38] J. Hodgdon. Patterns of Survival , 1952, The Yale Journal of Biology and Medicine.